Schizophrenia
📧 Sign up to get email alerts when something new happens for Schizophrenia.
Sign up freeTop drugs studied for this disease
-
FDA label_change · 2021-02-11FDA Approved: CLOZARIL — Supplemental Application (HLS Therapeutics (USA), Inc.)
The FDA approved a supplemental application for CLOZARIL (clozapine) submitted by HLS Therapeutics USA, Inc., updating the product labeling.
-
CLINICAL_TRIALS trial_result · 2021-02-09Clinical Trial Update: A Study to Evaluate the Effects of Basmisanil in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS) Treated With Antipsychotics [Phase 2]
Phase 2 clinical trial evaluating the effects of basmisanil in cognitive impairment associated with schizophrenia in patients treated with a…
-
CLINICAL_TRIALS trial_result · 2021-02-09Clinical Trial Update: A Randomized, Double-Blind, Placebo Controlled, Two-Period Cross-Over, Proof of Activity Study to Evaluate the Effects of TAK-041 on Motivational Anhedonia as Add-On to Antipsychotics in Participants With Stable Schizophrenia [Phase 2]
Phase 2 randomized, double-blind, placebo-controlled cross-over study evaluating TAK-041 as add-on to antipsychotics for motivational anhedo…
-
CLINICAL_TRIALS trial_result · 2021-02-05Clinical Trial Update: Pharmacologic Treatment of Acute Episode of Schizophrenia: a Real World Study [Phase 4]
Phase 4 real-world study evaluating pharmacologic treatment during acute episodes of schizophrenia.
-
CLINICAL_TRIALS trial_result · 2021-02-05Clinical Trial Update: MEtformin and Lorcaserin for WeighT Loss in Schizophrenia [Phase 4]
Phase 4 trial evaluating metformin and lorcaserin for weight loss in schizophrenia; study terminated with results posted.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2021-02-01FDA Approved: ARIPIPRAZOLE — Supplemental Application (Alembic Pharmaceuticals Inc.)
FDA approved a supplemental application for ARIPIPRAZOLE from Alembic Pharmaceuticals Inc., authorizing a generic aripiprazole product. The …
-
FDA approval · 2021-02-01FDA Approved: ARIPIPRAZOLE — Supplemental Application (Dr. Reddy's Laboratories Inc)
FDA approves Dr. Reddy's Laboratories' supplemental application to add a generic aripiprazole orally disintegrating tablet.
-
CLINICAL_TRIALS trial_result · 2021-01-27Clinical Trial Update: Effectiveness of Aripiprazole Long-acting Injection in Recent Onset and Chronic Schizophrenia Patients [Phase 4]
Phase 4 clinical trial update evaluating the effectiveness of aripiprazole long-acting injection in recent onset and chronic schizophrenia p…
-
CLINICAL_TRIALS trial_result · 2021-01-25Clinical Trial Update: A Multicenter Open-label Study Investigating the Pharmacokinetics and Safety of Aripiprazole IM Depot Formulation (OPC-14597 IMD) During Repeated Administration by Injection Into the Deltoid Muscle in Patients With Schizophrenia [Phase 1]
Phase 1 open-label study evaluating pharmacokinetics and safety of aripiprazole IM depot given by deltoid injections in schizophrenia patien…
-
CLINICAL_TRIALS trial_result · 2021-01-22Clinical Trial Update: Berberine as Adjuvant Treatment for Schizophrenia Patients [Phase 2, Phase 3]
A completed Phase 2/Phase 3 trial investigating berberine as an adjuvant treatment for schizophrenia and related psychotic disorders.
-
FDA approval · 2021-01-22FDA Approved: CHLORPROMAZINE HYDROCHLORIDE — Original Application (Lannett Company, Inc.)
FDA approved Lannett's generic chlorpromazine hydrochloride (ANDA 212996), authorizing the marketing of a generic chlorpromazine hydrochlori…
-
CLINICAL_TRIALS trial_result · 2021-01-19Clinical Trial Update: A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform [Phase 3]
Phase 3 trial comparing disease progression and modification after paliperidone palmitate long-acting injectable versus oral antipsychotics …
-
CLINICAL_TRIALS research · 2021-01-14Clinical Trial Update: Biomarkers in First Episode Schizophrenia
A completed clinical trial update focusing on biomarkers in first-episode schizophrenia, with posted results.
-
FDA approval · 2021-01-13FDA Approved: ZYPREXA RELPREVV — Supplemental Application (H2-Pharma LLC)
The FDA approved a supplemental application for ZYPREXA RELPREVV (OLANZAPINE PAMOATE) submitted by H2-Pharma LLC.
-
FDA approval · 2021-01-07FDA Approved: RISPERDAL CONSTA — Supplemental Application (Janssen Pharmaceuticals, Inc.)
The FDA approved a supplemental application for Risperdal Consta (risperidone long-acting injectable) submitted by Janssen Pharmaceuticals, …
-
FDA approval · 2021-01-07FDA Approved: FLUPHENAZINE HYDROCHLORIDE — Original Application (Dr. Reddys Laboratories Inc.)
FDA approved a generic version of fluphenazine hydrochloride under an Original Application for Dr. Reddy's Laboratories Inc.
-
FDA approval · 2020-12-31FDA Approved: OLANZAPINE — Original Application (Hisun Pharmaceuticals USA, Inc.)
FDA approved a generic olanzapine product under Hisun Pharmaceuticals USA, Inc.'s Original Application for olanzapine.
-
FDA approval · 2020-12-31FDA Approved: OLANZAPINE — Original Application (Hisun Pharmaceuticals USA, Inc.)
FDA approved the original abbreviated new drug application for olanzapine, a generic form manufactured by Hisun Pharmaceuticals USA, for use…
-
CLINICAL_TRIALS trial_result · 2020-12-29Clinical Trial Update: Aripiprazole IM Depot in the Acute Treatment of Adults With Schizophrenia [Phase 3]
Phase 3 clinical trial update for aripiprazole IM depot in acute treatment of adults with schizophrenia.
-
CLINICAL_TRIALS trial_result · 2020-12-24Clinical Trial Update: Effect of AQW051 on Cognitive Function in Patients With Chronic Stable Schizophrenia [Phase 2]
Phase 2 clinical trial evaluating AQW051 for cognitive function in patients with chronic stable schizophrenia has completed.
-
CLINICAL_TRIALS trial_result · 2020-12-24Clinical Trial Update: A Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients [Phase 2]
Phase 2 trial update evaluating AQW051 once-daily dosing on cognition in stable schizophrenia patients has completed.
-
CLINICAL_TRIALS trial_result · 2020-12-24Clinical Trial Update: Pharmacodynamic/Pharmacokinetic Study of AQW051 in Schizophrenia [Phase 1, Phase 2]
A pharmacodynamic/pharmacokinetic study of AQW051 in schizophrenia completed its Phase 1/2 trials.
-
CLINICAL_TRIALS trial_result · 2020-12-23Clinical Trial Update: Confirmatory Study of DSP-5423P in Patients With Schizophrenia [Phase 3]
A Phase 3 confirmatory study of DSP-5423P in schizophrenia has completed and results were posted in 2020.
-
CLINICAL_TRIALS trial_result · 2020-12-22Clinical Trial Update: Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia (ADVANCE) [Phase 2]
A Phase 2 trial evaluated pimavanserin as an adjunctive treatment for negative symptoms in schizophrenia; results completed and posted in 20…
-
CLINICAL_TRIALS trial_result · 2020-12-16Clinical Trial Update: Efficacy Study of Galantamine for Cognitive Impairments in Schizophrenia [Phase 4]
Phase 4 trial update evaluating galantamine for cognitive impairments in schizophrenia and schizoaffective disorder; results posted after co…